ClinicalTrials.gg
CompletedNCT05353101Updated Apr 29, 2022

Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis Trial

A Phase 1 interventional study of Cyclosporine 0.05% eye drops and Loteprednol Etabonate 0.5% and Tobramycin Eye Drops 0.3% in Vernal Keratoconjunctivitis and Cyclosporine 0.05% Eye Drops, sponsored by Second Affiliated Hospital of Nanchang University. Completed at 1 site in China. Open to participants aged 12 Years to 21 Years. Per ClinicalTrials.gov, last updated 2022-04-29.

Sponsored by Second Affiliated Hospital of Nanchang University · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled Jul 2020, registered Apr 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
12 Years to 21 Years
Sex
All
01

Study summary

To observe and compare the clinical efficacy of cyclosporine 0.05% eye drops with Loteprednol Etabonate 0.5% and Tobramycin Eye Drops 0.3% in the treatment of Vernal Keratoconjunctivitis in developing regions of China.

Read the detailed description

Vernal keratoconjunctivitis (VKC) is an allergic disease that severely affects the eyesight of adolescents. Vernal keratoconjunctivitis (VKC) usually occurs in temperate regions such as the Mediterranean region, the Middle East, Africa, Central America, and the Indian subcontinent. In the EU an estimated 3.2 per 10,000 inhabitants (0.03%). It occurs repeatedly and mainly involves type I and type IV hypersensitivity. long-term standardized treatment is necessary. Therefore, this research aims to compare the readily available cyclosporine 0.05% eye drops and Loteprednol Etabonate 0.5% and Tobramycin Eye Drops 0.3% in developing regions of Asia (China, Jiangxi Province) for long-term drug use in VKC patients in developing countries provide evidence.

02

Conditions studied

  • Vernal Keratoconjunctivitis
  • Cyclosporine 0.05% Eye Drops

Keywords

  • Cyclosporine 0.05% eye drops
  • Vernal Keratoconjunctivitis
  • Immunomodulator
  • Olopatadine Hydrochloride Eye Drops
03

In context

Conjunctivitis, Allergic

211 studies on the registry are indexed under Conjunctivitis, Allergic; 19 are open to participants now.

This study's enrollment of 48 is below the median of 87 across 175 interventional studies indexed under Conjunctivitis, Allergic.

Browse Conjunctivitis, Allergic studies →

Lead sponsor

Second Affiliated Hospital of Nanchang University is the lead sponsor of 85 studies on the registry; 52 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients had a noticeable seasonal, and recurrent Itching, Discomfort(burning, stinging, and foreign body sensation), Photophobia and tears, Viscous discharge;
  • Slit-lamp microscopy showed Conjunctival Hyperemia, Tarsal papillary, Limbal hypertrophy, Horner-Trantas dots, Keratitis in some patients;
  • No other medication history in recent 2 weeks;
  • Patients have high compliance and are willing to take drugs on time and return to the clinic in time

Exclusion criteria

Exclusion criteria:

  • with other related immune diseases or other drug use history in recent 2 weeks;
  • Patients with evident and severe organic diseases or mental diseases;
  • Low compliance, unable to take drugs on time or fail to return to the clinic on time.
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Cyclosporine 0.05% eye drops group

    The patients with VKC will receive Cyclosporine 0.05% eye drops or Loteprednol Etabonate 0.5% and Tobramycin Eye Drops 0.3% effect of Cyclosporine 0.05% eye drops would be evaluated during the follow-up visits.

    Drug: Cyclosporine 0.05% eye drops · Drug: Loteprednol Etabonate 0.5% and Tobramycin Eye Drops 0.3%

Interventions

  • DrugCyclosporineStudies of CyclosporineCyclosporine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Use of 0.05% CSA could significantly reduce IL-4, IL-5, IL-17A, and TNF in tears of VKC patients- α、 IFN- γ And eosinophil chemokine levels. Cyclosporine A (CSA) can effectively control ocular inflammation by blocking Th2 lymphocyte proliferation and IL-2 production. It can also inhibit the recruitment of eosinophils by inhibiting the release of histamine by mast cells and reducing the production of IL-5 further to improve its curative effect on VKC

  • DrugLoteprednol Etabonate 0.5% and Tobramycin Eye Drops 0.3%

    Drug page: Loteprednol EtabonateStudies of Loteprednol EtabonateLoteprednol Etabonate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Corticosteroids can inhibit the release of mast cells, block the chemotaxis of inflammatory cells, and reduce the number of mast cells and eosinophils in the conjunctiva. At the same time, it can inhibit phospholipase A2 and quickly alleviate symptoms and signs.

06

What researchers measure

Primary outcomes

  1. Changes of ocular signs

    The eye signs of the patients were observed under a slit lamp, including Conjunctival Hyperemia, Tarsal papillary, Limbal hypertrophy, Horner-Trantas dots, and Keratitis in some patients.The observer gives the corresponding score.The higher the score, the more serious it is (0-4 points)

    Time frame: Day 0#7#15#30 and 60d

  2. Changes of self-conscious symptoms

    The VAS scoring table was used for the patients' self-conscious symptoms, including pruritus, foreign body sensation, Photophobia and tears, and viscous secretions. The patients under study were self-scored at each review. 0-100 points, 0 indicates no discomfort, and 100 indicates the most significant pain. The intraocular pressure at each review was recorded by a non-contact tonometer.

    Time frame: Day 0#7#15#30 and 60d

07

Study locations

1 site
  • the Second Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Jun 2021, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2022
First posted
Apr 29, 2022
StartActual
Jul 1, 2020
Primary completionActual
Jun 1, 2021
CompletionActual
Jun 1, 2021
Last update
Apr 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05353101
Lead sponsor
Second Affiliated Hospital of Nanchang University
Responsible party
Yifeng Yu (Deputy chief physician of Ophthalmology center of the Second Affiliated Hospital of Nanchang University, Second Affiliated Hospital of Nanchang University) — Principal investigator
First posted
Apr 29, 2022
Start date
Jul 1, 2020
Primary completion
Jun 1, 2021
Completion
Jun 1, 2021
Last update
Apr 29, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cyclosporine · Loteprednol Etabonate

Start the discussion